Trends and Disparities in Systemic Lupus Erythematosus Mortality in the United States, 1999-2020: A Joinpoint Analysis of CDC WONDER National Mortality Data (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2007; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Despite advances in targeted therapy – including belimumab, voclosporin, and anifrolumab – it remains unknown whether population-level mortality gains have been equitably distributed across demographic and geographic subgroups. Despite a significant overall decline in SLE-related mortality (AAPC −1.90%), progress stalled after 2009 and reversed during the COVID-19 pandemic in 2020. Critically, the 3.7-fold Black/White mortality disparity has not narrowed over 22 years of observation, and Southern states continue to record rates 2.5-fold higher than New England. These findings indicate that advances in SLE therapy have not reached the populations bearing the greatest disease burden"
Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Novel Coronavirus Disease • Systemic Lupus Erythematosus
|
|
Madhuri Banoth1; Muhammed Sami Mughni2; Farukh Zaidi2
|